JOSEPH M PATTI Insider Trading $VXRT Vaxart, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JOSEPH M PATTI.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JOSEPH M PATTI. JOSEPH M PATTI is CEO and President in Aviragen Therapeutics, Inc. ($NABI) and EVP, Corporate Dev & Strategy in Aviragen Therapeutics, Inc. ($NABI).
JOSEPH M PATTI in Vaxart, Inc.
Trading Symbol: VXRTIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of JOSEPH M PATTI: CEO and President, EVP, Corporate Dev & Strategy
Holdings: 68,241 shares
Current Value: $77,795
Latest Transaction: Oct 02 2014
$VXRT Market Capitalization: $43.28M
$VXRT Previous Close: $1.14
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of JOSEPH M PATTI in Vaxart, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Oct 02 2014 | NABI | Aviragen Therapeut ... | PATTI JOSEPH M | CEO and President | Option Exercise | A | 2.45 | 475,000 | 1,163,750 | 475,000 | |
Jul 02 2014 | NABI | Aviragen Therapeut ... | PATTI JOSEPH M | EVP, Corporate Dev ... | Buy | P | 2.86 | 10,000 | 28,600 | 68,241 | 58.2 K to 68.2 K (+17.17 %) |
Jun 30 2014 | NABI | Aviragen Therapeut ... | PATTI JOSEPH M | EVP, Corporate Dev ... | Buy | P | 2.78 | 800 | 2,224 | 67,241 | 66.4 K to 67.2 K (+1.20 %) |
Jun 30 2014 | NABI | Aviragen Therapeut ... | PATTI JOSEPH M | EVP, Corporate Dev ... | Buy | P | 2.81 | 4,200 | 11,802 | 66,441 | 62.2 K to 66.4 K (+6.75 %) |
Jun 12 2014 | NABI | Aviragen Therapeut ... | PATTI JOSEPH M | EVP, Corporate Dev ... | Buy | P | 2.97 | 2,621 | 7,795 | 62,241 | 59.6 K to 62.2 K (+4.40 %) |
Jun 12 2014 | NABI | Aviragen Therapeut ... | PATTI JOSEPH M | EVP, Corporate Dev ... | Buy | P | 2.80 | 2,995 | 8,377 | 59,620 | 56.6 K to 59.6 K (+5.29 %) |
Jun 12 2014 | NABI | Aviragen Therapeut ... | PATTI JOSEPH M | EVP, Corporate Dev ... | Buy | P | 2.62 | 400 | 1,048 | 56,625 | 56.2 K to 56.6 K (+0.71 %) |
Jun 12 2014 | NABI | Aviragen Therapeut ... | PATTI JOSEPH M | EVP, Corporate Dev ... | Buy | P | 2.45 | 8,451 | 20,705 | 56,225 | 47.8 K to 56.2 K (+17.69 %) |
Dec 09 2013 | NABI | Aviragen Therapeut ... | PATTI JOSEPH M | EVP, Corporate Dev ... | Option Exercise | A | 0.00 | 15,625 | 0 | 15,625 | |
Dec 09 2013 | NABI | Aviragen Therapeut ... | PATTI JOSEPH M | EVP, Corporate Dev ... | Option Exercise | A | 4.13 | 62,500 | 258,125 | 62,500 |
Page: 1